Overview

Dalpiciclib Plus Letrozole and Capecitabine

Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Medical University Union Hospital
Treatments:
Capecitabine
Letrozole